Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 17:24 ET | Source: Robbins LLP

MoonLake Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against MLTX

A class action alleges MoonLake misled investors about SLK’s Nanobody advantages over BIMZELX. Phase 3 results showed no superiority, sending shares down 8
October 22, 2025 20:40 ET | Source: Robbins LLP

JSPR Investors Should Contact Robbins LLP Regarding the Upcoming Lead Plaintiff Deadline in the Jasper Therapeutics, Inc. Class Action

Jasper’s stock fell 55% after disclosures that it lacked adequate controls over third-party manufacturers, misstating its compliance and operations.
October 17, 2025 16:52 ET | Source: Robbins LLP

SVRA Lead Plaintiff Deadline (11/7/25) Reminder: Savara Inc. Investors Should Contact Robbins LLP for Information About the Class Action Lawsuit

Savara stock declined 31.7% after the FDA declined to file its MOLBREEVI application, citing incomplete chemistry, manufacturing, and controls information.
October 17, 2025 16:43 ET | Source: Robbins LLP

MLTX Investor Notice: Robbins LLP Reminds Stockholders of the Securities Fraud Class Action Against MoonLake Immunotherapeutics

Robbins LLP is Investigating Allegations that MoonLake Immunotherapeutics (MLTX) Mislead Investors Regarding the Efficacy of its Drug Candidate
October 10, 2025 19:24 ET | Source: Robbins LLP

ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.

Robbins LLP is Investigating Allegations that aTyr Pharma, Inc. (ATYR) Mislead Investors Regarding the Efficacy of its Drug Candidate
September 22, 2025 15:41 ET | Source: Robbins LLP

JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.

Robbins LLP is Investigating Allegations that Jasper Therapeutics, Inc. (JSPR) Misled Investors Regarding the Commercial Prospects of its Lead Product
September 12, 2025 16:01 ET | Source: Robbins LLP

SVRA Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Savara Inc. Securities Class Action Lawsuit

Robbins LLP is Investigating Allegations that Savara Inc. (SVRA) Misled Investors About the Viability of its Lead Drug Candidate
August 26, 2025 19:15 ET | Source: Robbins LLP

UNCY Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Unicycive Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. (UNCY) Misled Investors Regarding the Readiness of its Drug Prospect
July 28, 2025 08:10 ET | Source: Robbins LLP

REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc.

Robbins LLP is Investigating Allegations that Replimune Group, Inc. (REPL) Misled Investors Regarding the Viability of its IGNYTE Trial
July 25, 2025 15:28 ET | Source: Robbins LLP

CAPR Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Capricor Therapeutics, Inc. Securities Class Action

Robbins LLP is Investigating Allegations that Capricorn Therapeutics, Inc. (CAPR) Misled Investors Regarding the Viability of Deramiocel